Furthermore, relatives heterozygous for this mutation showed no risk of bleeding.19 This is also consistent with data from heterozygous GPVI-deficient mice, which showed no effect on tail bleeding time.17 GPVI-deficient platelets from patients were able to adhere to collagen, but no phosphatidyl serine exposure was observed.20 Preclinical studies have mostly focused on arterial thrombosis and not venous thrombosis. The gene discussed is GP6; the disease is Venous thrombosis.